These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23850707)

  • 41. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone marrow biopsy of aplastic anemia, myelodysplastic syndromes and myeloproliferative disorders.
    Kikuchi M
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1339-46. PubMed ID: 3247814
    [No Abstract]   [Full Text] [Related]  

  • 43. Pathogenesis and clinical variations in the myelodysplastic syndromes.
    Jacobs A; Clark RE
    Clin Haematol; 1986 Nov; 15(4):925-51. PubMed ID: 3552349
    [No Abstract]   [Full Text] [Related]  

  • 44. [Differential diagnosis between aplastic anemia and hypoplastic myelodysplastic syndromes: from the viewpoint of pediatrics].
    Hama A; Ito M; Kojima S
    Rinsho Ketsueki; 2012 Oct; 53(10):1485-91. PubMed ID: 23037720
    [No Abstract]   [Full Text] [Related]  

  • 45. [MR imaging findings of the femoral marrow in myelodysplastic syndrome].
    Tanaka O; Takagi S; Matsuura K; Ichikawa T; Kobayashi Y; Nagai J
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Oct; 55(12):837-44. PubMed ID: 8539101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
    Andrulis M; Capper D; Luft T; Hartmann C; Zentgraf H; von Deimling A
    Leuk Res; 2010 Aug; 34(8):1091-3. PubMed ID: 20227112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of immature platelet fraction in patients with myelodysplastic syndromes. Association with poor prognosis factors.
    Larruzea Ibarra A; Muñoz Marín L; Perea Durán G; Torra Puig M
    Clin Chem Lab Med; 2019 May; 57(6):e128-e130. PubMed ID: 30352024
    [No Abstract]   [Full Text] [Related]  

  • 48. A replicable CD271+ mesenchymal stromal cell density score: bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory.
    Gars E; Yousry SM; Babu D; Kurzer JH; George TI; Gratzinger D
    Leuk Lymphoma; 2017 Jul; 58(7):1730-1732. PubMed ID: 27808583
    [No Abstract]   [Full Text] [Related]  

  • 49. Advances in Bone Marrow Diagnostics of Patients with Cytopenia.
    Porwit A; Ziarkiewicz-Wroblewska B
    Pathobiology; 2019; 86(1):5-6. PubMed ID: 30476920
    [No Abstract]   [Full Text] [Related]  

  • 50. Myelodysplastic syndrome associated with acquired beta thalassemia: "BTMDS".
    Brunner AM; Steensma DP
    Am J Hematol; 2016 Aug; 91(8):E325-7. PubMed ID: 27121565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Empty marrow following previous irradiation in a patient with therapy-related myelodysplastic syndrome.
    Lee CH; Chen TY
    Br J Haematol; 2017 Dec; 179(5):703. PubMed ID: 28857127
    [No Abstract]   [Full Text] [Related]  

  • 52. "Myelodysplasia" from copper deficiency.
    Siddiqui S; Ramlal R
    Blood; 2019 Feb; 133(8):883. PubMed ID: 30792227
    [No Abstract]   [Full Text] [Related]  

  • 53. Magnetic resonance imaging reveals a markedly inhomogeneous distribution of marrow cellularity in a patient with myelodysplasia.
    Schick F; Weiss B; Einsele H
    Ann Hematol; 1995 Sep; 71(3):143-6. PubMed ID: 7548333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Symptomatic myelodysplasia with normal blood counts: a diagnostic enigma complicating the management of a patient with severe platelet dysfunction.
    van der Meeren S; de Becker A; de Waele M; de Smet D; Jochmans K
    Leuk Lymphoma; 2013 Jan; 54(1):192-4. PubMed ID: 22680770
    [No Abstract]   [Full Text] [Related]  

  • 55. The role of mast cells in bone marrow diseases.
    Ozdemir O; Savaşan S
    J Clin Pathol; 2004 Jan; 57(1):108-9. PubMed ID: 14693852
    [No Abstract]   [Full Text] [Related]  

  • 56. Apoptotic rate varies with detection methods in myelodysplastic syndromes: impact of method selection.
    Choi JW
    Eur J Haematol; 2002 Jul; 69(1):62-3. PubMed ID: 12270065
    [No Abstract]   [Full Text] [Related]  

  • 57. Evaluation of myelodysplasia syndrome screening during routine hematological analysis on the ADVIA 2120i.
    Koenders MM; Taal PH; Kluiters-De Hingh Y; Van Wijk EM
    Int J Lab Hematol; 2015 Apr; 37(2):e38-9. PubMed ID: 25046978
    [No Abstract]   [Full Text] [Related]  

  • 58. Association between mast cells and myelomonocytes.
    Saito N; Takemori N; Tachibana N; Hirai K; Onodera R
    J Clin Pathol; 1992 Jan; 45(1):89-90. PubMed ID: 1740528
    [No Abstract]   [Full Text] [Related]  

  • 59. Cytobiological and clinical aspects of tissue mast cell leukaemia.
    Coser P; Quaglino D; De Pasquale A; Colombetti V; Prinoth O
    Br J Haematol; 1980 May; 45(1):5-12. PubMed ID: 7378328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognosis in myelodysplasia.
    Lancet; 1986 Aug; 2(8504):436-7. PubMed ID: 2874419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.